Participating Companies

AgomAb Therapeutics
Our grow­ing pipe­line of high­ly spe­cif­ic mon­o­clo­n­al anti­bodies is de­signed to treat a range of acute and chron­ic con­di­tions that in­volve in­flam­ma­to­ry, metabolic and fi­brot­ic pro­cess­es. By com­bin­ing new sci­en­tif­ic in­sights with ro­bust de­vel­op­ment ex­per­tise, we are build­ing a com­pany to lead to the emer­gence of tru­ly re­gen­er­a­tive medicines. [more in­for­ma­tion]
AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
In the sum­mer of 2019, Am­ni­otics start­ed build­ing its GMP fa­cil­i­ty, and in June 2020 Am­ni­otics will sub­mit for man­u­fac­tur­ing au­tho­riza­tion of its cell ther­a­peu­tics to the Swedish MPA. Af­ter ap­pro­val Am­ni­otics in­tends to ini­ti­ate clin­i­cal trials, with its most ad­vance prod­uct Pul­mi­Cell™ which is a prod­uct based on MSCs from TAF se­lect­ed for their lung rel­e­vance. [more in­for­ma­tion]
Amolyt Pharma
Amo­lyt Phar­ma aims to fur­ther ex­pand and de­vel­op its port­fo­lio by lev­er­ag­ing its glob­al net­work in the field of en­docri­nol­o­gy and with sup­port from a strong syn­di­cate of in­ter­na­tio­n­al in­ves­tors. [more in­for­ma­tion]
Amplyx Pharmaceuticals
De­vel­op­ing first-in-class prod­ucts for the treat­ment of life-threat­en­ing in­fec­tions, with a near-term fo­cus on dead­ly fun­gal patho­gens in vul­n­er­able, im­mune com­pro­mised pa­tients. This makes them sus­cepti­ble to a new dis­ease—in­va­sive fun­gal in­fec­tions. By treat­ing their un­der­ly­ing con­di­tion, pa­tients are now open to a new life-threat­en­ing dis­ease. [more in­for­ma­tion]
Anima Biotech
We de­vel­op a pipe­line across ther­a­peu­tic ar­eas and part­n­er with Phar­ma for their tar­gets in­clud­ing our $1B+ col­lab­o­ra­tion with Lil­ly for the dis­cov­ery and de­vel­op­ment of trans­la­tion in­hibi­tors of sev­er­al tar­gets. [more in­for­ma­tion]
Arvelle Therapeutics
Arvelle is head­quar­tered in Switz­er­land and re­ceived start-up fi­nanc­ing of $207.8 mil­lion, one of the largest ini­tial fi­nanc­ing com­mit­ments for a Eu­ro­pean-fo­cused bio­phar­ma­ceu­ti­cal com­pany, with in­vest­ments from a glob­al syn­di­cate in­clud­ing No­vaQuest Cap­i­tal Ma­n­age­ment, BRV Cap­i­tal Ma­n­age­ment, LSP, H.I.G. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,531 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr7,051 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for im­proved Q of life, treat­ment out­comes and re­source uti­l­iza­tion. [more in­for­ma­tion]
Cantargia AB [CANTA:ST] SKr1,559 MM MCap
The ba­sis for this is the pro­tein IL1RAP that is in­volved in a num­ber of dis­eas­es and where Can­tar­gia has estab­lished a plat­form. Can­tar­gia's other pro­ject, CAN10, is in the pre­clin­i­cal phase and is aim­ing to de­vel­op an IL1RAP bind­ing anti­body block­ing IL-1, IL-33 and IL-36 - op­ti­mised for the treat­ment of sys­temic scle­ro­sis and my­o­cardi­tis. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
Deutsche Bank AG [DB] $27,130 MM MCap
Deutsche Bank’s ADR team is part of the Trust & Agen­cy Ser­vices busi­ness within the new­ly cre­at­ed Cor­po­rate Bank Di­vi­sion. Deutsche Bank was ap­point­ed as DR Bank for the largest Life Sci­ences sec­tor ADR IPO of 2019 with the $582m Nas­daq list­ing of Genmab A/S, con­firm­ing our po­si­tion as the lead­ing is­suer of cap­i­tal in the US ADR mar­kets. [more in­for­ma­tion]
Dy­nacure is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on im­prov­ing the lives of pa­tients with rare and or­phan dis­eas­es. The Dy­nacure team lev­er­ages its proven track re­cord in rare dis­ease drug de­vel­op­ment to build a pipe­line of nov­el drugs. [more in­for­ma­tion]
Glycostem Therapeutics
Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €145 MM MCap
AT­AC plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. Lead prod­uct HDP-101, for blood can­cer, is ex­pect­ed to start clin­i­cal dev' end of 2021. Out-li­cens­ing the AT­AC tech­nol­o­gy us­ing the part­n­ers’ anti­bodies to cre­ate new AT­ACs and ex­pect long term in­come streams and ear­ly tech­nol­o­gy vali­da­tion. [more in­for­ma­tion]
HO­RA­MA’s ap­proach is based on vec­tor tech­nol­o­gy us­ing non-patho­genic, re­com­bi­nant ade­no-as­so­ci­at­ed virus­es (rAAV) and new gen­er­a­tion of mod­i­fied rAAV (mrAAV). V-Bio, Turenne Cap­i­tal, Id­In­vest Part­n­ers, GO Cap­i­tal, Sham In­no­va­tion Sant&ea­cute; and Omnes Cap­i­tal al­so par­ti­ci­pat­ed in the round. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
Kiadis Pharma N.V. [KDS-AMS]
NK-cell plat­form ad­min­is­tered as ad­junct I-O on top of HSCT. Launched FIH POC trial in r/r AML pa­tients (Feb 2020); set to launch ad­di­tio­n­al HSCT trial lat­er in 2020 w/in­ter­im da­ta exp 2021. Pre­sent­ing new da­ta on ex-vi­vo FC21 ex­pand­ed NK-cell ther­a­py in 13 pa­tients at EBMT in 2020. Estab­lished POC in 37 pa­tients to­tal. [more in­for­ma­tion]
Maxcyte [MXCT:LN]
glob­al cell ther­a­py com­pany pro­vid­ing pro­pri­e­tary non-vi­ral cell en­gi­neer­ing tech­nol­o­gy for the next gen­er­a­tion of cell-based ther­a­pies in­clud­ing gene edit­ing and im­muno-on­col­o­gy. Max­Cyte may be seen as a play on the cell ther­a­py mar­ket with its blue chip client base. [more in­for­ma­tion]
Nasdaq, Inc. [NDAQ] $28,814 MM MCap
Nas­daq is pri­mar­i­ly known for its equi­ty exchange, but in ad­di­tion to its mar­ket ser­vices busi­ness (about 35% of sales), the com­pany sells and dis­tributes exchange da­ta through its in­for­ma­tion ser­vices seg­ment (30%). In­for­ma­tion ser­vices of­fers Nas­daq-brand­ed in­dex­es to as­set ma­n­agers and in­ves­tors. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Lead prod­uct, icos­abu­tate has been found safe and ef­fec­tive in two pri­or phase 2 clin­i­cal studies for treat­ment of hy­per­trig­lyc­eridemia and mixed dys­lipi­demia and is cur­rent­ly in clin­i­cal de­vel­op­ment for NASH. The icos­abu­tate phase 2b ICO­NA NASH trial is sche­d­uled to read­out in the first quar­ter of 2023. Two ad­di­tio­n­al SE­FAs are in clin­i­cal de­vel­op­ment; SE­FA 1024 is in phase 1 to be de­vel­oped for dys­lipi­demia and SE­FA 6179, [more in­for­ma­tion]
Oculis Pharma
The com­pany's nov­el eye-drop treat­ments are based on its pro­pri­e­tary sol­u­bi­l­iz­ing nano­par­ti­cle (SNP) tech­nol­o­gy that im­proves both the abil­i­ty to for­mu­late drugs as eye drops and their bioa­vai­l­a­bil­i­ty in the eye tis­sues in­clud­ing both the front and the back of the eye, en­abling hos­pi­tals to pro­vide clients with tech­no­log­i­cal ad­vance­ment in oc­u­lar drug de­liv­ery. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­val and up to $550M sales mile­s­tones. [more in­for­ma­tion]
De­vel­op­er of bio­phar­ma­ceu­ti­cals for the treat­ment of an­gio­ge­n­e­sis-re­lat­ed di­s­or­ders. The com­pany is en­gaged in the dis­cov­ery and de­vel­op­ment of nov­el bio­phar­ma­ceu­ti­cal prod­ucts and of­fers anti­body deri­va­tives for the treat­ment of cer­tain can­cers can­cer, rheu­ma­toid arthri­tis and age-re­lat­ed mac­u­lar de­gen­er­a­tion. [more in­for­ma­tion]
PwC is a glob­al net­work of firms de­liv­er­ing as­su­r­ance, tax and con­sult­ing ser­vices for your busi­ness. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
De­vel­op­er of tar­get­ed on­col­o­gy ther­a­pies in­clud­ing he­ma­tol­o­gy/solid tu­mors. RVU120 is whol­ly-owned first-in-class oral CD­K8/19 in­hibi­tor in Phase I for AML/MDS Small molecule, syn­thet­ic lethal­i­ty plat­form in pre-clin­i­cal de­vel­op­ment in­clud­ing nov­el tar­gets WRN and PRMT5. [more in­for­ma­tion]
Sequana Medical [SEQUA]
Se­qua­na Med­i­cal is a com­mer­cial stage med­i­cal de­vice com­pany de­vel­op­ing the al­fa­pump plat­form for the ma­n­age­ment of fluid over­load in liv­er dis­ease, ma­lig­nant ascites and heart fail­ure. In Eu­rope, the al­fa­pump is CE-marked for the ma­n­age­ment of re­frac­to­ry ascites due to liv­er cir­rho­sis and ma­lig­nant ascites and is in­clud­ed in key clin­i­cal prac­tice guide­lines. [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]